About the Editor Gerri S. Hall, Ph.D.

Transcription

1 About the Editor Gerri S. Hall, Ph.D. Dr. Hall s professional career has been focused on clinical microbiology: direct clinical activities of various areas such as bacteriology, mycobacteria, STD testing, and antimicrobial susceptibility testing of bacteria and fungi. Her laboratory performs clinically relevant patient care testing and research in these areas. She also teaches within the Department of Clinical Pathology as well as externally and is actively involved in teaching in the Cleveland Clinic Foundation Lerner School of Medicine of Case Western Reserve University. G.S. Hall (ed.), Interactions of Yeasts, Moulds, and Antifungal Agents: How to Detect Resistance, DOI / , Springer Science+Business Media, LLC

2 A Abelcet, 5, 6 Acremonium spp., 119 AFST. See Antifungal susceptibility testing (AFST) Agar methods, antifungal susceptibility testing on chromagar, direct testing, 79 disk diffusion, 79 E test, MIC determination vs. CLSI method, 80 gradient technique, vs. microdilution broth methods, 81 reproducible method, 80 fluconazole testing, 81 Alamar blue, colorimetric method, 76 Alternaria alternata, 118 AmBisome (LAmB), 5, 6 Amorolfine, Amphotericin absorption, 3 brand names, 1 Candida spp., clinical outcomes, distribution, 3 drug interactions, 4 5 efficacy of, 6 excretion, 3 4 formulation, 1 mechanism of action, 3 MIC interpretation, 6 pharmacodynamic target, 4 primary uses, 2 resistance, 5 6 side effects of, 4 spectrum of activity, 2 structure, 1 Anidulafungin activity, 39 adverse effects, 40 brand name/formulation, 38 Candida spp., clinical correlations, drug interactions, 40 fungal infection, treatment for, 41 interpretive criteria, 41 mechanism, MIC interpretation, 41 pharmacodynamic target, pharmacokinetics, 39 primary uses, 38 resistance, 40 Antifungal agents amorolfine, azoles imidazoles (see Imidazoles) triazoles (see Triazoles) butenafine hydrochloride, butoconazole/butoconazole nitrate, ciclopirox, dermatophytes, treatment for, 90 echinocandins anidulafungin (see Anidulafungin) caspofungin, micafungin (see Micafungin) econazole, fluorocytosine (5-FC) griseofulvin, naftifine, oxiconazole, polyenes amphotericin (see Amphotericin) Nystatin (see Nystatin) 161

3 162 Antifungal agents (cont.) potassium iodide, sertaconazole, terbinafine hydrochloride, tolnaftate, Antifungal susceptibility testing (AFST) agar method on chromagar, direct testing, 79 disk diffusion, 79 E test, MIC determinations, fluconazole testing, 81 broth microdilution method bioscreen microdilution, 78 Candida species, 76 Candifast, 77 carboxyfluorescein diacetate, 78 chloromethylfluorescein diacetate, 78 Cryptococcus species, 77 Fungites, 77 Integral System Yeast, 77 Sensititre YeastOne Colorimetric system, 76, 77 Vitek 2, 77 XTT, tetrazolium salt, 78 clinical correlations Aspergillus spp., 143, 145 Candida spp. ( see Candida spp.) Cryptococcus neoformans, 146 dimorphic fungi, organism-drug combinations, clinical utility and factors, 132 principles, rule, standardized methods, combination testing, 84 committee report on, 66 guidelines, clinical laboratory, minimum fungicidal concentration, 83 mould testing analyzing data, CLSI M38-A2, 71 endpoint determination, 72 history, macrobroth method, 72 target percent transmission readings, non-growth-based methods ergosterol assay, 82 flow cytometry, 82 molecular method, 83 patients management, 147 reference method, 76 yeast testing antibiotic medium 3, 69 break points for, 68 endpoints, 67 Etest and YeastOne panels, 71 EUCAST method, 69 history, 66 M44-A, 71 in M27-A3, 67 MIC determination, 68 RPMI 1640 medium, rule, 69 species resistance, 69, 70 turbidity, 68 ARTEMIS Global Surveillance Study, 97 Aspergillus spp. A. flavus, A. fumigatus, A. nidulans, 112 A. niger, A. terreus, 111 A. versicolor, 111 clinical correlations, AFST, 143, 145 ECVs determination for, 112 synergy and, 112 Azoles cytochrome P450 inhibition, 10 imidazoles clotrimazole (see Clotrimazole) ketoconazole (see Ketoconazole) miconazole (see Miconazole) side effects, 11 triazoles albaconazole, fluconazole, itraconazole, posaconazole, ravuconazole, voriconazole (see Voriconazole) B BioMerieux Vitek, 77 Black (Dematiaceous) fungi Alternaria spp., 118 Curvularia spp., Exophiala spp., 119 Blastomyces dermatitidis, 126 Broth microdilution method bioscreen microdilution, 78 Candida species, 76 Candifast, 77 carboxyfluorescein diacetate, 78 chloromethylfluorescein diacetate, 78

4 163 Cryptococcus species, 77 Fungites, 77 Integral System Yeast, 77 Sensititre YeastOne Colorimetric system, 76, 77 Vitek 2, 77 XTT, tetrazolium salt, 78 Butenafine hydrochloride activity, 50 brand name/formulation, 49 drug interactions, 51 mechanism, 50 MIC interpretations, 51 pharmacokinetics, 50 primary uses, resistance, 51 side effects, 50 treatment, 51 Butoconazole, C Candida spp. clinical correlations amphotericin B, echinocandins, fluconazole, flucytosine, 140 itraconazole, voriconazole, susceptibility patterns of C. albicans, 97, C. glabrata, 98 C. guilliermondii, 101 C. krusei, 100 C. lusitaniae, C. parapsilosis, 99 C. rugosa, 101 C. tropicalis, Carboxyfluorescein diacetate (CFDA), 78 Caspofungin activity, 33 brand name/formulation, 32 broth microdilution method, 78 against Candida sp., 35 Candida spp., clinical correlations, drug interactions, 34 mechanism, 33 MIC interpretations, pharmacodynamic target, 33 pharmacokinetics, 33 primary uses, 32 resistance, 34 side effects, 34 Ciclopirox, Cladophialophora carrionii, Clinical and Laboratory Standards Institute (CLSI) agar method on chromagar, direct testing, 79 disk diffusion, 79 E test, MIC determinations, fluconazole testing, 81 AST (see Antifungal) broth microdilution method bioscreen microdilution, 78 Candida species, 76 Candifast, 77 carboxyfluorescein diacetate, 78 chloromethylfluorescein diacetate, 78 Cryptococcus species, 77 Fungites, 77 Integral System Yeast, 77 Sensititre YeastOne Colorimetric system, 76, 77 Vitek 2, 77 XTT, tetrazolium salt, 78 combination testing, 84 dermatophytes (see Dermatophytes) minimum fungicidal concentration, 83 non-growth-based methods ergosterol assay, 82 flow cytometry, 82 molecular method, 83 reference method, 76 Clinical utility, antifungal susceptibility testing factors, 132 principles, rule, standardized methods, Clotrimazole activity, 12 adverse reactions, brand name/formulations, candidal infection, used for, 13 drug interactions, mechanism, 12 MIC interpretation, 13 pharmacokinetics primary uses, 12 resistance, 13 CLSI. See Clinical and Laboratory Standards Institute (CLSI) Coccidioides immitis, Cryptococcus neoformans, 146 Cryptococcus spp. clinical correlations, 146

5 164 Cryptococcus spp. (cont.) susceptibility patterns of C. gattii, 103 C. neoformans, other species, 103 Curvularia sp., 121 D Dermatophytes antifungal agents, 90 clinical manifestations, 90 CLSI reference method, keratinized tissues, humans, 89 susceptibility testing clinical applications, 94 optimal growth conditions, standardization, Dimorphic fungi clinical correlations, AFST, susceptibility testing Blastomyces dermatitidis, 126 Coccidioides immitis, Histoplasma capsulatum, Paracoccidioides brasiliensis, 127 Penicillium marneffei, 128 Sporothrix schenckii, Disk diffusion method, 79 Drug interactions amphotericin, 4 5 butenafine hydrochloride, 51 clotrimazole, echinocandins anidulafungin, 40 caspofungin, 34 micafungin, 37 5-fluorocytosine (5-FC), 10 grisefulvin, 42 imidazoles clotrimazole, ketoconazole, 16 miconazole, nystatin, 7 oral antifungal agents ( see Antifungal agents) terbinafine hydrochloride, triazoles albaconazole, 31 fluconazole, itraconazole, posaconazole, 28 ravuconazole, voriconazole, 24 E Echinocandins anidulafungin (see Anidulafungin) Candida spp., clinical outcomes bloodstream infection isolates, 142 data analysis, ECVs, 143 MIC interpretive breakpoints, 143, 145 pharmacodynamics, 142 and in vitro resistance, 143, 144 caspofungin (see Caspofungin) micafungin activity, 36 brand name/formulation, 35 drug interactions, 37 esophageal candidiasis, 38 hypersensitivity reactions, mechanism, 35 MIC interpretation, 38 pharmacodynamic target, 36 pharmacokinetics, 36 primary uses, 35 resistance, 37 side effects, 37 Econazole, Epidemiological cutoff values (ECVs), 112 Epidermophyton, 90 Ergosterol assay, 82 E test, antifungal susceptibility testing vs. CLSI method, 80 gradient technique, vs. microdilution broth methods, 81 reproducible method, 80 European Community on Antifungal Susceptibility Testing (EUCAST), 69 Exophiala spp., 119 F 5-FC. See 5-Fluorocytosine (5-FC) FDA. See Food and Drug Administration (FDA) Flow cytometry, 82 Fluconazole activity, 17 agar-based methods, 81 brand name/formulations, 17 Candida spp., clinical correlations CLSI interpretations, 134 dose/mic ratio relationship, MIC, low and high levels of, 135 MIC ranges, analysis of,

6 165 mucosal and invasive infections, S-DD range, 135 drug interactions, mechanism, 18 MIC interpretation, 19 pharmacodynamic target, 18 pharmacokinetics, 18 primary uses, 17 resistance, 19 side effects, yeast, 19 Flucytosine Candida spp. and, fluorocytosine, 9 5-Fluorocytosine (5-FC) absorption, 9 brand names, 8 distribution, 9 drug interactions, 10 excretion, 9 formulation, 8 mechanism, 9 MIC interpretation, 10 pharmacodynamic target, 9 primary uses, 8 resistance, 10 side effects, 9 10 spectrum of activity, 8 structure, 8 Fonsecaea pedrosoi, 122 Food and Drug Administration (FDA), 90 Fungus Testing Laboratory, 120 Fusarium spp., antifungal susceptibility testing, G Grisefulvin activity, 42 brand names/formulation, 41 mechanism, 42 MIC interpretation, 42 pharmacokinetics, 42 primary uses, 41 resistance, 42 side effects/drug interactions, 42 tinea capitis, 43 H Histoplasma capsulatum, I Imidazoles clotrimazole, ketoconazole, miconazole, Itraconazole absorption, activity, 20 adverse reactions, brand names/formulation, 20 Candida spp., clinical correlations, distribution, 21 drug interactions, excretion, 21 mechanism of action, 20 MIC interpretation, 22 mould, 22 pharmacodynamic target, 21 primary uses, 20 resistance, 22 K Ketoconazole activity, 15 adverse reactions, 16 brand name/formulations, 15 dermatophyte infections, treatment of, 17 drug interactions, 16 mechanism, 16 MIC interpretations, 17 pharmacokinetics, 16 primary uses, 15 resistance, 16 Kirby-Bauer method, 71 M MBC. See Minimum bactericidal concentration Mentax cream, Methylene blue-glucose, 71 MFC. See Minimum fungicidal concentration MIC. See Minimum inhibitory concentration Micafungin activity, 36 brand name/formulation, 35 Candida spp., clinical correlations, drug interactions, 37

7 166 Micafungin (cont.) esophageal candidiasis, 38 hypersensitivity reactions, mechanism, 35 MIC interpretation, 38 pharmacodynamic target, 36 pharmacokinetics, 36 primary uses, 35 resistance, 37 side effects, 37 Miconazole activity, 14 brand name/formulation, 13 dosage of, 15 mechanism, 14 MIC interpretations, 15 pharmacokinetics, 14 primary uses, 14 resistance, side effects, 14 Microsporum, 90 Minimum bactericidal concentration (MBC), 83 Minimum effective concentration (MEC), antifungal activity, 35, 38, 67, 141 Minimum fungicidal concentration (MFC), 50, 83 Minimum inhibitory concentration (MIC), 66, 91 amphotericin, 6 anidulafungin, 41 butenafine hydrochloride, 51 caspofungin, clotrimazole, 13 distribution, 142 and dose ratio relationship, 136 echinocandins, interpretive breakpoints, fluorocytosine, 10 grisefulvin, 42 itraconazole, 22 micafungin, 38 miconazole, 15 nystatin, 7 terbinafine hydrochloride, 45 voriconazole, 25 Mould testing analyzing data, CLSI M38-A2, 71 endpoint determination, 72 history, macrobroth method, 72 target percent transmission readings, Mueller-Hinton agar, 71 N Naftifine, National Committee of Clinical Laboratory Standards (NCCLS), 75 Neo-Sensitabs tablets, 79 Nystatin brand names, 6 drug interactions, 7 formulation, 6 liposomal formulation, 8 mechanism, 7 MIC interpretation, 7 pharmacokinetics, 7 primary uses, 6 resistance, 7 side effects of, 7 spectrum of activity, 6 7 O Oxiconazole activity, 59 adverse reaction, 59 brand name/formulation, 58 drug interactions, 59 fungal infection, treatment for, 60 mechanism of action, 59 MIC interpretation, 59 primary uses, 59 P Paecilomyces spp., Paracoccidioides brasiliensis, 127 Penicillium marneffei, 128 Penicillium spp., 116 Phialophora verrucosa, 119 Potassium iodide adverse reaction, 61 brand name/formulation, 60 drug interactions, 61 mechanism of action, 60 pharmacokinetics, primary uses, 60 sporotrichosis, treatment for, 61 Pseudallescheria boydii, 117 Q Quality control ranges, antifungal agents, 93

8 167 R Ravuconazole, Resistance. See specific Antifungal agents Rhizopus oryzae, antifungal susceptibility testing, 119 Rhodotorula spp., Rifabutin, 11, 24, 28 Rifampin, 11, 34 RPMI 1640 medium, 91 S Sabouraud dextrose broth, 91 Saccharomyces cerevisiae, 105 Scedosporium S. apiospermum, S. prolificans, 114 Scopulariopsis brevicaulis, S-DD. See Susceptible dose-dependent Senititre YeastOne colorimetric method broth microdilution method, 76 S. apiospermum, 114 SENTRY study, 98 Sertaconazole, antifungal agents, Sporothrix schenckii, Susceptibility patterns black (dematiaceous) fungi Alternaria spp., 118 Curvularia spp., Exophiala spp., 119 combination testing, antifungal agents, 122 hyaline moulds Acremonium spp., 117 Aspergillus spp. ( see Aspergillus spp.) Fusarium spp., Paecilomyces spp., Penicillium spp., 116 Scedosporium spp., Scopulariopsis spp., yeasts Candida spp. ( see Candida spp.) Cryptococcus spp. ( see Cryptococcus spp.) Rhodotorula spp., Saccharomyces cerevisiae, 104 Trichosporon spp., 104 Zygomycetes Myocladus corymbifereus, 117 Rhizopus oryzae, 117 Rhizopus spp., 118 Saksenaea spp., 118 Susceptibility testing antifungal susceptibility testing ( see Antifungal susceptibility testing (AFST)) dermatophytes antifungal agents, 90 clinical manifestations, 90 CLSI reference method, keratinized tissues, humans, 89 susceptibility testing clinical applications, 94 optimal growth conditions, standardization, dimorphic fungi Blastomyces dermatitidis, 126 Coccidioides immitis, Histoplasma capsulatum, Paracoccidioides brasiliensis, 127 Penicillium marneffei, 128 Sporothrix schenckii, Susceptible dose-dependent (S-DD), 134 T Terbinafine hydrochloride activity, 43 brand name/formulation, 43 drug interactions, mechanism, 43 MIC interpretations, 45 nail infection, treatment for, 45 pharmacokinetics absorption, distribution, 44 excretion, 44 primary uses, 43 resistance, 45 side effects, 44 Tolnaftate, Triazoles albaconazole, fluconazole, itraconazole, posaconazole, ravuconazole, voriconazole (see Voriconazole) Trichophyton species, 91 Trichosporon spp., 104 V Voriconazole absorption, 23

9 168 Voriconazole (cont.) activity, 23 adverse effects, 25 brand name/formulation, 22 Candida spp., clinical correlations analysis of, 139 breakpoints, efficacy of, h MIC, CLSI and EUCAST methods, 139, 140 investigator assessment vs. MIC, S-DD category, 139 distribution, 23 drug interactions, 24 excretion, mechanism, 23 MIC interpretation, 25 pharmacodynamic target, 24 primary uses, resistance, 25 side effects, 24 Zygomycetes infection, 26 Y Yeast, antifungal susceptibility testing of antibiotic medium 3, 69 break points for, 68 CLSI M27-A3, 67 endpoints, 67, 68 Etest and YeastOne panels, 71 EUCAST method, 69 history, 66 M44-A, 71 MIC determination, 68 RPMI 1640 medium, rule, 69 species resistance, 69, 70 turbidity, 68 Yeast nitrogen base (YNB) medium, 91 Z Zygomycetes Myocladus corymbifereus, 117 Rhizopus oryzae, 117 Rhizopus spp., 118 Saksenaea spp., 118